House Energy and Commerce Committee leaders yesterday sent letters to nine contract pharmacies that participate in the 340B drug savings program requesting information about their participation in the program. The letters sought information on contracting practices; the distance between covered entities and contract pharmacies; to what degree contract pharmacies prevent duplicate discounts or diversion in the program; and whether contract pharmacies ensure low-income uninsured patients do not face high drug costs despite the program’s discount. The letters follow a June Government Accountability Office report recommending that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B requirements.
 

Related News Articles

Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
The AHA today submitted a letter to the Office of Science and Technology Policy in response to its request for information on regulatory reform for artificial…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…